RSV Prevention Products and Severe RSV-Associated Disease Among Infants
{{output}}
Importance: A long-acting monoclonal antibody (nirsevimab) for use in infants aged 7 months or younger and an antenatal respiratory syncytial virus (RSV) vaccine (RSVpreF) became available in Washington state in 2023. ... ...
